The weekly litigation news digest is live. Subscribe now

IP Verse

Injectable In-Situ Crosslinked Hydrogel And The Preparation Method And Use Thereof - EP2353612

The patent EP2353612 was granted to Bioregen Biomedical Changzhou on Jan 3, 2018. The application was filed on Sep 8, 2009 under application number EP09820182A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP2353612

BIOREGEN BIOMEDICAL CHANGZHOU
Application Number
EP09820182A
Filing Date
Sep 8, 2009
Status
Opposition Rejected
Sep 15, 2023
Publication Date
Jan 3, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
CROMA PHARMA GESELLSCHAFTOct 3, 2018SCHWARZ & PARTNER PATENTANWALTE -

Patent Citations (15) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONCN101190891
DESCRIPTIONCN101200504
DESCRIPTIONEP0185070
DESCRIPTIONUS4582865
DESCRIPTIONUS4713448
DESCRIPTIONUS6624245
DESCRIPTIONUS6884788
DESCRIPTIONUS7196180
DESCRIPTIONWO2004037164
DESCRIPTIONWO2005056608
DESCRIPTIONWO2008098019
INTERNATIONAL-SEARCH-REPORTUS6624245
OPPOSITIONWO2008077172
SEARCHUS2007269488
SEARCHWO2006113407

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents